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Recombination may be an important mechanism for increasing variation in retroviral populations. Retroviral recombination has been demonstrated in tissue culture systems by artificially creating doubly infected
cells. Evidence for retroviral recombination in vivo is indirect and is based principally on the identification of
apparently mosaic human immunodeficiency virus type 1 genomes from phylogenetic analyses of viral sequences. We infected a rhesus monkey with two different molecularly cloned strains of simian immunodeficiency virus. One strain of virus had a deletion in vpx and vpr, and the other strain had a deletion in nef. Each
strain on its own induced low virus loads and was nonpathogenic in rhesus monkeys. When injected simultaneously into separate legs of the same monkey, persistent high virus loads and declines in CD41 lymphocyte
concentrations were observed. Analysis of proviral DNA isolated directly from peripheral blood mononuclear
cells showed that full-length, nondeleted SIVmac239 predominated by 2 weeks after infection. These results
provide direct experimental evidence for genetic recombination between two different retroviral strains in an
infected host. The results illustrate the ease and rapidity with which recombination can occur in an infected
animal and the selection that can occur for variants generated by genetic recombination.
nature. It is not known whether mosaic viral genomes appeared as rare events in history and continue to be propagated
in the population. Further, the time frame required to evolve
into a different phylogenetic type is unknown. Retroviral recombination within an infected host has not to our knowledge
ever been directly demonstrated. We thus designed an experiment that would readily detect SIV recombination in an infected monkey.

Ten major subtypes of human immunodeficiency virus type
1 (HIV-1), represented by phylogenetic groups A through J,
are currently recognized (21). Individual HIV-1 genomes that
possess subgenomic regions that cluster with different subtypes
have been discovered (3, 7, 9, 11, 19, 26). Such mosaic genomes
have also been identified for HIV-2 and simian immunodeficiency virus (SIV) (10, 24, 25). It has been presumed that these
mosaic structures arose through the process of genetic recombination (24, 25).
Recombination between two different strains of retrovirus
can occur only when their RNA genomes are brought together
into the same virus particle to create a heterozygous virion
(16). Reverse transcription of heterozygous RNA genomes by
a copy choice mechanism will produce genetic recombinants
(16, 17, 28). A heterozygous virion is produced by the packaging of two different RNA molecules by a cell that is infected
with two strains of virus. Although doubly infected cells have
been generated artificially in cell culture systems, none have
yet been identified in an infected host. Whether HIV-1 has
ample opportunity for recombination in an infected host remains unclear. The uncertainty derives from questions regarding the numbers of cells harboring HIV-1 genetic information
(1, 6, 23, 27), the timing and frequency of full expression of
proviral genomes (22), the extent to which superinfection resistance will prevent a single infected cell from becoming infected with a second strain (2, 4, 13, 20), and the efficiency of
the recombination process itself.
Evidence for the occurrence of recombination with HIV-1,
HIV-2, and SIV is based on phylogenetic analyses of individual
viral genomes (3, 7, 9–11, 19, 24–26) and thus is indirect in

MATERIALS AND METHODS
Isolation of DNA from peripheral blood mononuclear cells (PBMC). For the
isolation of DNA, cells were lysed in 0.6% sodium dodecyl sulfate and treated
with 150 mg of proteinase K per ml at 56°C for 1.5 h. Three-tenths of a volume
of saturated NaCl was added, and the solution was clarified by centrifugation.
The NaCl step was repeated, and DNA was precipitated from the clarified
supernatant with isopropanol. The DNA was washed with ethanol and air dried.
Dried DNA pellets were resuspended in 179 ml of ultrapure, sterile H2O and
incubated at room temperature overnight. Twenty microliters of 103 T4 DNA
ligase buffer and 40 U of T4 DNA ligase were added, and the DNA suspensions
were mixed gently by tapping. The ligation reaction mixture was incubated at
room temperature for 1 h. Samples were stored finally at 220°C.
PCR. Double-nested PCR was performed with outer primers 5823VPX and
9816FEN3U in the first round and inner primers 5864VPX and 9788FEN3U in
the second round. Primer sequences were as follows: 5823VPX, 59-CAGGGAG
AGAATCCCACCTGG-39; 9816FEN3U, 59-GAAGGCCTCTTGCGGTTAGC
C-39; 5864VPX, 59-TAGGAGAGGCCTTCGAATGGC-39; 9788FEN3U, 59-AA
CCTCTTCCTCTGACAGGCC-39. Each round of PCR consisted of 28 cycles of
amplification with 5 ml of reaction mixture transferred from the first-round to the
second-round reaction. Two units of rTth DNA polymerase XL was used for
each reaction along with manufacturer’s buffer (Perkin-Elmer, Foster City, Calif.). Other reaction components were 1.2 mM Mg(OAc)2, 200 mM (each) deoxynucleoside triphosphates, 30 pm (each) primer, and 1 mg of genomic DNA
template in a total volume of 100 ml. Round 1 amplification conditions consisted
of a hot start (94°C, 1 min; 70°C, 2 min, during which enzyme was added), a
two-step cycling profile (94°C, 15 s; 70°C, 5 min; 28 cycles), and a final incubation
(72°C, 10 min). Round 2 amplification conditions were similar to those for round
1 with the exception of using 68°C in the two-step cycle profile instead of 70°C.
All reactions were performed on a GeneAmp PCR System 9600 thermal cycler
(Perkin-Elmer).
Sequencing. For direct sequencing of PCR-amplified DNA, three 100-ml reaction mixtures were combined and concentrated to a volume of 40 to 75 ml.
Primers from PCR were removed by purification on CHROMA SPIN-400 col-
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TABLE 1. Virological data

Week no.

Virus loada

Antigenemiab
(ng/ml)

0
1
2
4
6
8
12
20
27

NTc
12,345
1,371
4,115
8,230
24,691
12,345
8,230
8,230

,0.05
,0.05
0.90
,0.05
,0.05
NT
NT
NT
NT

a
b
c

Number of PBMC needed to isolate virus.
SIV p27 antigen capture (Immunotech, West Brook, Maine).
NT, not tested.

umns (Clontech Laboratories, Inc., Palo Alto, Calif.). Sequencing was performed
with the Sequenase DNA sequencing kit (United States Biochemical Corp.,
Cleveland, Ohio). Sequencing primers were as follows: 6177VPX, 59-TAAACC
ACCTACCAAGGGAGC-39; 6574XPV, 59-CTCAAGGGTGTCTCCATGTC39; 9437NEF, 59-GGAAGATGGATACTCGCAAT-39; and 9759FEN, 59-CTA
AGATTCTATGTCTTCTTGC-39.

RESULTS
Infection of the rhesus monkey. A rhesus monkey was infected with two attenuated strains of SIV, Dvpxvpr and Dnef.
Both are deletion mutants derived from the molecularly cloned
parental strain SIVmac239, which causes AIDS in rhesus monkeys (18). The vpxvpr genes and the nef gene are required for
full pathogenicity in rhesus monkeys. In the absence of vpx and
vpr, or in the absence of nef, virus loads are low and AIDS does
not develop (12, 18). The level of attenuation resulting from
the vpxvpr deletion is similar to or slightly greater than that
resulting from the deletion of nef (12, 18). Peak levels of the
numbers of infectious cells in PBMC in the weeks immediately
following infection are 20- to 1,000-fold lower with these mutants than with the parental SIVmac239. The numbers of infectious cells that persist for prolonged periods are also at least
100- to 1,000-fold lower with these mutant viruses than with
the parental SIVmac239 (12, 18).
The rhesus monkey was inoculated intravenously in one leg
with Dvpxvpr virus containing 154 ng of p27 and in the other
leg with Dnef virus, also containing 154 ng of p27. The same
stocks of Dvpxvpr and Dnef viruses have been used previously
to infect rhesus monkeys without any evidence of high virus
loads, disease progression, or wild-type virus (8, 12, 18). Blood
samples were obtained at various times after inoculation and
used to monitor several parameters. A spike of p27 antigenemia corresponding to 0.9 ng/ml was detected in plasma 2
weeks after inoculation (Table 1). Such a spike has always been
detected at week 2 with wild-type parental SIVmac239 but not
with either of the deletion mutants used (12, 18). High cellassociated virus loads, measured as the frequency of infectious
cells in PBMC (8, 12, 18), were induced and maintained in this
animal, similar to the pattern obtained with the parental SIVmac239 (30) but dissimilar to the pattern obtained with either
of the mutant viruses (8, 12, 18) (Table 1). Furthermore, the
frequency of CD41 cells in PBMC decreased from 51 and 52%
at weeks 1 and 0, respectively, to 33% at week 12 and 27% at
week 28 (data not shown).
Amplification of proviral DNA. The above results suggested
that a recombination event had taken place between the two
viruses to yield nondeleted, parental virus. To examine this
possibility, total cell DNA was prepared from PBMC isolated
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at 2 and 6 weeks postinfection, and proviral sequences were
amplified by PCR.
In order to provide precise size standards, CEMx174 cell
cultures (15) were separately infected with the full-length
parental virus SIVmac239, deletion mutant Dvpxvpr, and
deletion mutant Dnef. Total cell DNA was prepared by the
same DNA preparation method that was used for the PBMC.
For negative controls, DNA was prepared from uninfected
CEMx174 cells and from uninfected rhesus monkey PBMC.
PCR primers that span a DNA sequence of approximately 4 kb
that encompasses both the vpxvpr and nef deletions were designed. PCR amplification with DNA from PBMC samples
from the infected monkey yielded a fragment of approximately
4 kb (Fig. 1). When subjected to the same double-nested PCR
procedures in parallel in multiple independent experiments,
both of the negative DNA samples were completely devoid of
amplified bands, indicating the absence of PCR contamination.
A representative CEMx174 DNA control is shown in Fig. 1.
Restriction enzyme analysis of amplified proviral DNA. The
entire region spanning both the vpxvpr and nef deletions had to
be amplified in one piece in order to detect the presence of
recombinant sequences. Since the sizes of the vpxvpr and nef
deletions were 265 and 182 bp, respectively, their presence
could not be established unambiguously from the sizes of the
amplified fragments in the gel shown in Fig. 1. The ;4-kb
amplified fragments were therefore digested with restriction
enzymes SphI and SstI and were further analyzed by agarose
gel electrophoresis.
The SphI enzyme cut is diagnostic for the presence of the
vpxvpr deletion. Restriction of the ;4-kb PCR product with
SphI yielded the expected fragments of 3,386 and 628 bp for
full-length SIVmac239 and fragments of 3,386 and 363 bp for
the Dvpxvpr mutant; the presence of the vpxvpr deletion can
thus be determined by the size of the smaller SphI fragment:
363 versus 628 bp. When amplified DNAs from the week 2 and
week 6 PBMC samples were cut with SphI, only the 628- and
3,386-bp fragments were detected. The sizes of the SphI fragments were identical to those of the full-length, parental SIVmac239 and clearly distinct from those of the Dvpxvpr control
(Fig. 2A).
Similarly, the SstI enzyme cut is diagnostic for the presence

FIG. 1. PCR amplification of SIV sequences. One microgram of total cell
DNA was used for amplification by double-nested PCR. The products were
separated by agarose gel electrophoresis and visualized by ethidium bromide
staining. Lanes labeled week 2 and week 6 represent total cell DNA prepared
from PBMC isolated at 2 and 6 weeks, respectively, after coinfection of the
rhesus monkey. The remaining lanes show the products from total cell DNA
prepared from CEMx174 cells infected with the following viruses: (i) SIVmac239, full-length parental virus; (ii) Dvpxvpr, attenuated SIVmac239 with
deletions in vpx and vpr; (iii) Dnef, attenuated SIVmac239 with a deletion in nef;
(iv) Dvpxvpr plus Dnef, a mixture of 0.5 mg each of total cell DNA prepared from
cells infected separately with Dvpxvpr and Dnef viruses; (vi) CEMx174, uninfected cells.
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FIG. 2. Restriction enzyme analysis of PCR-amplified SIV DNA. The ;4-kb
fragments shown in Fig. 1 were digested with SphI (A) and SstI (B). SphI is
diagnostic for the presence of the vpxvpr deletion, while SstI is diagnostic for the
presence of the nef deletion. See the legend to Fig. 1 for a definition of lanes.

of the nef deletion. Restriction of the ;4-kb PCR product with
SstI yielded the expected fragments of 3,408 and 606 bp for the
full-length SIVmac239 and fragments of 3,408 and 424 bp for
the nef mutant; the presence of the nef deletion can thus be
determined by the size of the smaller SstI fragment: 424 versus
606 bp. The sizes of the SstI fragments for weeks 2 and 6 were
identical to those of the full-length, parental SIVmac239 and
clearly distinct from those of the Dnef control (Fig. 2B). These
results demonstrate that only full-length, recombinant SIVmac239 was detected at weeks 2 and 6 after coinfection of the
rhesus monkey.
Controls for PCR recombination. In order to rule out the
possibility that the observed results were due to selective PCR
recombination, 0.5 mg of total cell DNA prepared from cells
infected individually with the Dvpxvpr and Dnef mutants was
mixed and amplified alongside the other samples in doublenested PCR (Fig. 1). Restriction enzyme analysis of the ;4-kb
PCR product with SphI and SstI showed a mixture of the two
deletion mutants (Fig. 2; representative of six independent
experiments). These results indicate that the full-length, recombinant SIVmac239 observed at weeks 2 and 6 in the coinfected rhesus monkey was not the result of PCR recombination.
Sequencing of recombinant proviruses. The PCR-amplified
DNAs from PBMC taken at weeks 2 and 6 were directly sequenced. Primers were located upstream and downstream of
the regions corresponding to the vpxvpr and nef deletions. The
sequence of the PCR-amplified DNA matched exactly that of
the full-length, parental SIVmac239; no changes were found
within either of the regions. Therefore, the observed restoration to full-length size (Fig. 1 and 2) was not due to insertion
of another sequence, duplication, or DNA rearrangement.
DISCUSSION
The studies described in this report provide direct experimental evidence for genetic recombination between two SIV
strains in an infected animal. A rhesus monkey was inoculated
with two different strains of SIV, and recombinant virus was
found to predominate by 2 weeks postinfection. Recombinant
virus was strongly selected in these experiments because both
of the starting strains were significantly impaired in their ability
to replicate in monkeys.
Recent studies of HIV-1-infected individuals reveal that the
long asymptomatic phase of infection is not a latent period but
is a time of high activity for the virus (14, 29). It has been
estimated that the minimum daily production of HIV-1 particles in infected individuals is on the order of 109 virions per day
(14). It has also been estimated that HIV-1 replicates at a rate
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of at least 300 cycles per year, resulting in an estimated 3,000
generations during the average 10-year period of infection (5).
Despite the availability of this highly quantitative information
on viral dynamics, assessment of the opportunity for HIV-1
recombination in an infected host is unfortunately not possible.
Uncertainty over the numbers of cells replicating HIV-1 genetic information at any one time (1, 6, 23, 27) and the efficiency of superinfection resistance prevent any such calculation of the likelihood of recombination events.
The rhesus monkey used for this study can be estimated to
contain approximately 1011 total body lymphocytes. The numerical odds of obtaining 10 doubly infected cells at peak virus
load would require only 1 in 105 cells replicating each deletion
mutant virus. This theoretical calculation does not take into
account the unknown contribution of superinfection resistance
or the possibility of localized replication in discrete areas of
lymphoid tissue. Nonetheless, our results indicate that there is
ample opportunity for genetic recombination even with these
attenuated mutants. The opportunity for recombination with
wild-type viruses, which replicate to much higher levels than
the strains used in our study, is expected to be considerably
greater. Recombinants with a selective advantage, such as that
described in the results reported here, could significantly impact the progression of events in vivo.
Our studies with SIV demonstrate not only that AIDS virus
recombination can occur readily in an individual but also that
recombinants can be selected rapidly by biological forces. Two
weakly replicating SIVs recombined in a coinfected rhesus
monkey to yield a fully replication-competent virus with pathogenic potential. Recombination must be viewed as a viable
mechanism for increasing AIDS virus variation in infected
individuals.
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